Caremark Issues Statement on Questcor's (QCOR) Acthar Gel
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/19/2024
- Nasdaq, S&P tumble as Netflix, chip stocks drag; AmEx boosts Dow
- Sony/Apollo bid for Paramount could be worth as much as $29 billion - Source
- Netflix Q1 earnings top estimates on blowout subscriber growth
- Nasdaq tumbles, Treasuries dip amid earnings, geopolitical crosscurrents
- Gold prices rally past $2,400 on reports of Israel strikes on Iran
- Tritium DCFC Limited (DCFC): Three Australian subsidiaries were determined to be insolvent or likely to become insolvent
- Hasbro (HAS) Announces Resignation of Cynthia Williams, President of Wizards of the Coast and Hasbro Gaming
- Jabil falls after placing CEO on paid leave amid internal investigation
- Frontier Communications (FYBR) says third party had gained unauthorized access to portions of its information technology environment
- Ibotta (IBTA) Prices 6.56M Share IPO at $88/sh
- Midday movers: Netflix, Super Micro fall; Paramount Global gains
- After-hours movers: Netflix, Intuitive Surgical, Nordstrom, KB Home
- Midday movers: Tesla, Blackstone, Las Vegas Sands fall; DR Horton rises
- After-hours movers: Alcoa rises; Equifax and Las Vegas Sands fall
- Midday movers: Travelers, JB Hunt fall; United Airlines rises
Questcor (QCOR) Updates on Study of Acthar for MS Patients When Regular Treatment Doesn't
March 11, 2013 11:42 AM EDTQuestcor (Nasdaq: QCOR) shares are on the rise following more positive data tied to its ACTH treatment, Acthar.
According to Bloomberg, the American Academy Neurology released data from a new study outlining the benefits of Acthar on multiple sclerosis (MS) which isn't being well controlled via regular treatment. The release, posted on Science Daily is reprinted below:
A new study suggests that treatment with adrenocorticotropic hormone (ACTH) may be helpful for people whose multiple sclerosis (MS) is not well-controlled through their regular treatment. The study was released... More
Questcor (QCOR) Updates on Study of Acthar for MS Patients When Regular Treatment Doesn't
March 11, 2013 11:42 AM EDTQuestcor (Nasdaq: QCOR) shares are on the rise following more positive data tied to its ACTH treatment, Acthar.
According to Bloomberg, the American Academy Neurology released data from a new study outlining the benefits of Acthar on multiple sclerosis (MS) which isn't being well controlled via regular treatment. The release, posted on Science Daily is reprinted below:
A new study suggests that treatment with adrenocorticotropic hormone (ACTH) may be helpful for people whose multiple sclerosis (MS) is not well-controlled through their regular treatment. The study was released... More
